Rakovina Therapeutics Inc · TSXV:RKV
Rakovina Therapeutics — Investor Presentation (May 2025)
20 slides from Rakovina Therapeutics's investor presentation, May 2025
Slide 1: Advancing Cancer Care with the Precision & Power of AI
ADVANCING CANCER CARE WITH THE PRECISION & POWER OF AI TSX.V: RKV Investor Presentation | Q2 2025
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the investors who will pa
Slide 3: Accelerating Drug Discovery to Save Lives
ACCELERATING DRUG DISCOVERY TO SAVE LIVES Our mission has always been about improving the lives of those battling cancer. Now, with a robust Artificial Intelligence (AI) platform on our side, we are moving into a new era of research speed and accuracy. Using Best in Class AI algorithms, we quickly a
Slide 4: Rakovina Therapeutics Investment Thesis Powered by AI
RAKOVINA THERAPEUTICS INVESTMENT THESIS POWERED BY AI FOCUSED ON DDR RESPONSE-BASED THERAPIES Founded in 2021 to focus on the development of new DNA-damage (DDR) response-based therapies for the treatment of cancer EXCLUSIVE ACCESS TO BEST-IN-CLASS AI PLATFORMS Exclusive access to utilize the Deep D
Slide 5: Experienced Team with a Track Record of Success
EXPERIENCED TEAM WITH A TRACK RECORD OF SUCCESS Our team has extensive expertise in drug discovery, preclinical and clinical development and partnering to advance breakthrough innovations to become potential life-changing treatments in the oncology field. JEFFREY BACHA, BSC, MBA ARTEM CHERKASOV, PHD
Slide 6: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD DENNIS BROWN, PHD LEONARD POST, PHD Chair, Scientific Advisory Board (SAB)/Director SAB/Senior Drug Development Advisor • Involved in cancer drug discovery and development for 35+ years and currently serves as a • 35+ years of drug development and leadership experience in t
Slide 7: AI Powered Drug Development
RAKOVINA THERAPEUTICS AI POWERED DRUG DEVELOPMENT Patients can not wait years to get the treatment they need today and tomorrow. Traditional Drug Development AI Driven Drug Development Thousands of potential drug candidates BILLIONS of potential drug candidates DEVELOPMENT PATH STAGE 1 Selecting a S
Slide 8: A New Era with Drug Discovery Through AI Collaborations
HOW IT WORKS A NEW ERA WITH DRUG Deep Docking1 and EnkiTM are DISCOVERY THROUGH distinct computational AI COLLABORATIONS modeling techniques to rapidly evaluate billions of compounds to identify novel • Exclusive access to Deep Docking1 AI therapeutic drug candidates. platform for DNA-damage respons
Slide 9: Deep Docking AI Platform: Real-World Impact on COVID-19
DEEP DOCKING1 AI PLATFORM: REAL-WORLD IMPACT ON COVID-19 The team behind Deep Docking partnered with Nvidia, Dell and UBC Advanced Research Computing (ARC) to identify potential COVID-19 therapeutics from large libraries. “Even with a supercomputer, it would take years to screen billions of compound
Slide 10: DNA-Damage Response (DDR)
75% of solid tumors harbor a DDR defect1 DNA-DAMAGE RESPONSE (DDR) • DDRs are naturally occurring mechanisms that detect • and repair DNA damage within our cells. Many cancers harbor a defect in these natural repair $18B DDR annual market potential by 20302 mechanisms allowing mutations to accumulat
Slide 11: Combining AI Platforms with Rakovina Capabilities for Rapid DDR Drug Development
COMBINING AI PLATFORMS WITH RAKOVINA CAPABILITIES FOR RAPID DDR DRUG DEVELOPMENT COMPOUND SCREENING & LEAD OPTIMIZATION PHASE only 3-4 months from 3 years COMPOUND SCREENING DRUG VALIDATION LAB QUALIFIED CLINICAL LEADS 5B+ ULTRA LARGE DATASETS INTEGRATED PLATFORM FOR ADVANCING DDR DRUG FOR DRUG SCRE
Slide 12: First AI DDR Target: CNS Penetrant Selective Inhibitor of PARP-1
FIRST AI DDR TARGET: A CNS PENETRANT SELECTIVE INHIBITOR OF PARP-1 • PARP is a type of enzyme that helps repair DNA damage in cells. • PARP inhibitors are a type of drug that works by preventing certain types of cancer cells from repairing damaged DNA, committing them to die. • 1st generation PARP-1
Slide 13: Second AI DDR Target: CNS Penetrant Selective Inhibitor of ATR
SECOND AI DDR TARGET: A CNS PENETRANT SELECTIVE INHIBITOR OF ATR • ATR (ataxia telangiectasia and Rad3-related protein) is a critical kinase that senses and responds to DNA damage by activating repair pathways and orchestrating cell cycle checkpoints. • Cancer cells, which often have high levels of
Slide 14: Rakovina Therapeutics' Drug Development Portfolio
RAKOVINA THERAPEUTICS’ DRUG DEVELOPMENT PORTFOLIO Development Stage Multiple high-value DDR Drug targets already Indication Development Pipeline Drug Lead Pre- Clinical validated. Discovery Optimization clinical Trials ✓ PARP kt-3283 PARP-resistant ✓ ATM adult & childhood kt-3000 series cancers ✓ CY
Slide 15: Upcoming Catalysts
kt-3000 * kt-2000AI ** kt-5000AI*** UPCOMING CATALYSTS Best-in-class PARP/HDAC Best-in-class PARP-1 selective inhibitor, Best-in-class ATR inhibitor, brain penetrant cancer therapy inhibitor, cancer therapy brain penetrant cancer therapy 2024 2025 2026 Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug
Slide 16: Investments in DNA-Damage Response by Multi-National Pharmaceutical Corporations
INVESTMENTS IN DNA-DAMAGE RESPONSE BY MULTI-NATIONAL PHARMACEUTICAL CORPORATIONS RECENT DDR TRANSACTIONS Oct 2023 PARP-inhibitor • $1.5B ($169M upfront) • FDA status at signing: phase 1 License Agreement Jun 2022 ATR-inhibitor • $1.2B ($125M upfront) • FDA status at signing: preclinical License Agre
Slide 17: Market Summary – Pre Financing / Consolidation
MARKET SUMMARY – PRE FINANCING / CONSOLIDATION EXCHANGE TSX Venture Exchange (TSXV) OWNERSHIP SUMMARY SYMBOL RKV Edison Oncology SECTOR / INDUSTRY Biopharmaceuticals / Oncology Holding Corp. 17% 52 WEEK RANGE1 CAD $0.05 - 0.23 Reporting Insiders, SHARES OUTSTANDING 140,042,575 Institution / 6% FULLY
Slide 18: Market Summary – Post Financing / Consolidation
MARKET SUMMARY – POST FINANCING / CONSOLIDATION EXCHANGE TSX Venture Exchange (TSXV) OWNERSHIP SUMMARY SYMBOL RKV Edison Oncology SECTOR / INDUSTRY Biopharmaceuticals / Oncology Holding Corp. 12% 52 WEEK RANGE1 N/A Reporting Insiders, 4% SHARES OUTSTANDING 19,804,258 Institution / FULLY DILUTED 36,3
Slide 19: Why Invest in Rakovina Therapeutics
WHY INVEST IN RAKOVINA THERAPEUTICS A new paradigm in drug discovery and therapeutic intervention to treat cancer. $18B ADDRESSABLE DDR MARKET Broad cancer application targeting 75% of all solid tumors that harbor a DNA-Damage response defect. BRING-TO-MARKET MANAGEMENT TEAM Deep expertise in drug d
Slide 20: Over 70% of Pharmaceutical Breakthroughs Stem from Small Biotech
OVER 70% OF PHARMACEUTICAL BREAKTHROUGHS ir@rakovinatherapeutics.com STEM FROM THE EFFORTS OF SMALL BIOTECH rakovinatherapeutics.com COMPANIES LIKE RAKOVINA THERAPEUTICS. Suite 720, 999 West Broadway Vancouver, British Columbia CanadaTSX.V: V5Z 1K5 RKV / 20
Rakovina Therapeutics — Investor Presentation (May 2025) on 6ix